Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

Erika Borlenghi, MD, Chiara Pagani, MD, Michele Malagola, MD, Diego Bertoli, PhD, Francesca Schieppati, MD, Silvana Archetti, PhD, Angela Passi, MD, Cinzia Lamorgese, Chiara Cattaneo, MD, Nicola Polverelli, Margherita Sciumé, Rosa Daffini, MD, Doriana Gramegna, MD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 2695.

https://doi.org/10.1182/blood-2019-126074

Published: 2019

Journal Articles

Molecular Monitoring of NPM1 Is a Useful Tool for Detecting Early-Stage Relapse and to Guide Pre-Emptive Treatment Approaches in Patients with NPM1-Mutated Acute Myeloid Leukemia

Francesca Schieppati, MD, Angela Passi, MD, Erika Borlenghi, MD, Cinzia Lamorgese, Giuseppina Ruggeri, MD, Marco Chiarini, MSc, Viviana Giustini, MSc, Michele Malagola, MD, Chiara Cattaneo, MD, Margherita Sciumé, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 3931.

https://doi.org/10.1182/blood.V130.Suppl_1.3931.3931

Published: 2017

Journal Articles

The Detection of Minimal Residual Disease By Multiparameter Flow Cytometry Predicts a Higher Risk of Relapse in Patients with ELN Intermediate Risk Acute Myeloid Leukemia Where Molecular Markers Are Not Available

Erika Borlenghi, MD, Mirko Farina, MD, Marco Chiarini, MSC, Viviana Giustini, MSC, Cinzia Lamorgese, Angela Passi, MD, Enrico Morello, MD, Luisa Imberti, MD, Giuseppe Rossi, MD

Blood (2016) 128 (22): 2882.

https://doi.org/10.1182/blood.V128.22.2882.2882

Published: 2016

Journal Articles

Validating the Patient's "Fitness" Criteria Proposed to Guide Treatment Decision in Elderly AML: a Multicenter Study on a Population-Based Series of 362 Patients By the Network "Rete Ematologica Lombarda" (REL)

Erika Borlenghi, MD, Chiara Pagani, MD, Claudia Basilico, MD, Massimo Bernardi, MD, Nicola Fracchiolla, MD, Francesca Guidotti, MD, Laura Marbello, MD, Andrea Ferrario, MD, Carlo Messina, MD, Emanuele Ravano, MD, Cinzia Lamorgese, Marta Petullà, Giuseppe Rossi, MD

Blood (2014) 124 (21): 279.

https://doi.org/10.1182/blood.V124.21.279.279

Published: 2014

Journal Articles

Immune Defects of B- and T-Cell Compartments in Natalizumab-Induced Progressive Multifocal Leukoencephalopathy,

Alessandra Sottini, Ruggero Capra, Cinzia Zanotti, Marco Chiarini, Federico Serana, Cinzia Lamorgese, Marina Motta, MD, Doris Ricotta, Luigi Caimi, Luisa Imberti

Blood (2011) 118 (21): 3228.

https://doi.org/10.1182/blood.V118.21.3228.3228

Published: 2011

NARROW

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

Molecular Monitoring of NPM1 Is a Useful Tool for Detecting Early-Stage Relapse and to Guide Pre-Emptive Treatment Approaches in Patients with NPM1-Mutated Acute Myeloid Leukemia

The Detection of Minimal Residual Disease By Multiparameter Flow Cytometry Predicts a Higher Risk of Relapse in Patients with ELN Intermediate Risk Acute Myeloid Leukemia Where Molecular Markers Are Not Available

Validating the Patient's "Fitness" Criteria Proposed to Guide Treatment Decision in Elderly AML: a Multicenter Study on a Population-Based Series of 362 Patients By the Network "Rete Ematologica Lombarda" (REL)

Immune Defects of B- and T-Cell Compartments in Natalizumab-Induced Progressive Multifocal Leukoencephalopathy,

Email alerts

ASH Publications

American Society of Hematology

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

Molecular Monitoring of NPM1 Is a Useful Tool for Detecting Early-Stage Relapse and to Guide Pre-Emptive Treatment Approaches in Patients with NPM1-Mutated Acute Myeloid Leukemia

The Detection of Minimal Residual Disease By Multiparameter Flow Cytometry Predicts a Higher Risk of Relapse in Patients with ELN Intermediate Risk Acute Myeloid Leukemia Where Molecular Markers Are Not Available

Validating the Patient's "Fitness" Criteria Proposed to Guide Treatment Decision in Elderly AML: a Multicenter Study on a Population-Based Series of 362 Patients By the Network "Rete Ematologica Lombarda" (REL)

Immune Defects of B- and T-Cell Compartments in Natalizumab-Induced Progressive Multifocal Leukoencephalopathy,

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only